Abstract
As well known, the increase in life expectancy and the better physical condition of people in western countries will lead in the next 20 years to a dramatic development of neurodegenerative diseases, especially of dementia that could be considered one of the most important problems in clinical, social and economic fields for the future. Therefore, the differential diagnosis of the various types of dementia is a critical step for patients, clinicians and researchers since an accurate “in vivo” diagnosis can lead to a better patients management. Neuroimaging techniques and in particular the most diffuse and affordable single photon emission computed tomography (SPECT) have provided useful information about dementia disorders and these methods, on the basis of the recent advances, will have an increasingly important role in research and clinical practice. The purpose of this article is to analyze the different SPECT techniques now available which proved clinically useful in correctly formulating the differential diagnosis of dementia.
Keywords: Brain SPECT, perfusion functional imaging, 123I Ioflupane dopaminegic imaging, dementia differential diagnosis.
[1]
Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer disease. Nat Rev Neurol 7(3): 137-52.(2011);
[2]
Matthews FE, Brayne C, Lowe J, McKeith I, Wharton SB, Ince P. Epidemiological pathology of dementia: attributable-risks at death in the Medical Research Council Cognitive Function and Ageing Study. PLoS Med 6(11) e1000180(2009);
[3]
Knopman DS, DeKosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, et al. Practice parameter: diagnosis of dementia (an evidence-based review). report of the quality standards subcommittee of the american academy of neurology. Neurology 56(9): 1143-53.(2001);
[4]
Harris JM, Thompson JC, Gall C, Richardson AM, Neary D, du Plessis D, et al. Do NIA-AA criteria distinguish Alzheimer’s disease from frontotemporal dementia? Alzheimers Dement 11(2): 207-15.(2015);
[5]
Gold G, Bouras C, Canuto A, Bergallo MF, Herrmann FR, Hof PR, et al. Clinicopathological validation study of four sets of clinical criteria for vascular dementia. Am J Psychiatry 159(1): 82-7.(2002);
[6]
Litvan I, Bhatia KP, Burn DJ, Goetz CG, Lang AE, McKeith I, et al. Movement Disorders Society Scientific Issues Committee. Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord 18(5): 467-86.(2003);
[7]
McKeith I, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet 356(9247): 2031-6.(2000);
[8]
Marsh L. Treatment of Lewy-body dementias and psychopathology. Lancet Neurol 9(10): 943-5.(2010);
[9]
Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil 308 Study Group. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 61(4): 479-86.(2003);
[10]
Clarfield AM. The decreasing prevalence of reversible dementias: an updated meta-analysis. Arch Intern Med 163(18): 2219-29.(2003);
[11]
Román GC, Sachdev P, Royall DR, Bullock RA, Orgogozo JM, López-Pousa S, et al. Vascular cognitive disorder: a new diagnostic category updating vascular cognitive impairment and vascular dementia. J Neurol Sci 226(1-2): 81-7.(2004);
[12]
Karantzoulis S, Galvin JE. Update on dementia with lewy bodies. Curr Transl Geriatr Exp Gerontol Rep 2(3): 196-204.(2013);
[13]
AGS Clinical Practice Committee. Guidelines abstracted from the American Academy of Neurology’s dementia guidelines for early detection, diagnosis, and management of dementia. J Am Geriatr Soc 51(6): 869-73.(2003);
[14]
Matsuda H. Role of neuroimaging in Alzheimer’s disease, with emphasis on brain perfusion SPECT. J Nucl Med 48(8): 1289-300.(2007);
[15]
Devous MD. Functional brain imaging in the dementias: role in early detection, differential diagnosis, and longitudinal studies. Eur J Nucl Med Mol Imaging 29(12): 1685-96.(2002);
[16]
Kemp PM, Hoffmann SA, Holmes C, Bolt L, Ward T, Holmes RB, et al. The contribution of statistical parametric mapping in the assessment of precuneal and medial temporal lobe perfusion by 99mTc-HMPAO SPECT in mild Alzheimer’s and Lewy body dementia. Nucl Med Commun 26(12): 1099-106.(2005);
[17]
Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos I, Kapsalaki E, et al. Perfusion SPECT studies with mapping of Brodmann areas in differentiating Alzheimer’s disease from frontotemporal degeneration syndromes. Nucl Med Commun 33(12): 1267-76.(2012);
[18]
Andersen AR. 99mTc-D,L-hexamethylene-propyleneamine oxime (99mTc-HMPAO): basic kinetic studies of a tracer of cerebral blood flow. Cerebrovasc Brain Metab Rev 1(4): 288-318.(1989);
[19]
Vallabhajosula S, Zimmerman RE, Picard M, Stritzke P, Mena I, Hellman RS, et al. Technetium-99m ECD: a new brain imaging agent: in vivo kinetics and biodistribution studies in normal human subjects. J Nucl Med 30(5): 599-604.(1989);
[20]
Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 45(4): 594-607.(2004);
[21]
Talbot PR, Lloyd JJ, Snowden JS, Neary D, Testa HJ. A clinical role for 99mTc-HMPAO SPECT in the investigation of dementia? J Neurol Neurosurg Psychiatry 64(3): 306-13.(1998);
[22]
Defebvre LJ, Leduc V, Duhamel A, Lecouffe P, Pasquier F, Lamy-Lhullier C, et al. Technetium HMPAO SPECT study in dementia with Lewy bodies, Alzheimer’s disease and idiopathic Parkinson’s disease. J Nucl Med 40(6): 956-62.(1999);
[23]
Pasquier J, Michel BF, Brenot-Rossi I, Hassan-Sebbag N, Sauvan R, Gastaut JL. Value of (99m)Tc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging 29(10): 1342-8.(2002);
[24]
Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology 56(5): 643-9.(2001);
[25]
McNeill R, Sare GM, Manoharan M, Testa HJ, Mann DM, Neary D, et al. Accuracy of single-photon emission computed tomography in differentiating frontotemporal dementia from Alzheimer’s disease. J Neurol Neurosurg Psychiatry 78(4): 350-5.(2007);
[26]
Borroni B, Grassi M, Agosti C, Paghera B, Alberici A, Di Luca M, et al. Latent profile analysis in frontotemporal lobar degeneration and related disorders: clinical presentation and SPECT functional correlates. BMC Neurol 7-9.(2007);
[27]
Ebmeier KP, Prentice N, Ryman A, Halloran E, Rimmington JE, Best JK, et al. Temporal lobe abnormalities in dementia and depression: a study using high resolution single photon emission tomography and magnetic resonance imaging. J Neurol Neurosurg Psychiatry 63(5): 597-604.(1997);
[28]
Starkstein SE, Sabe L, Petracca G, Chemerinski E, Kuzis G, Merello M, et al. Neuropsychological and psychiatric differences between Alzheimer’s disease and Parkinson’s disease with dementia. J Neurol Neurosurg Psychiatry 61(4): 381-7.(1996);
[29]
Yoshikawa T, Murase K, Oku N, Imaizumi M, Takasawa M, Rishu P, et al. Heterogeneity of cerebral blood flow in Alzheimer disease and vascular dementia. AJNR Am J Neuroradiol 24(7): 1341-7.(2003);
[30]
Dougall NJ, Bruggink S, Ebmeier KP. Systematic review of the diagnostic accuracy of 99mTc-HMPAO-SPECT in dementia. Am J Geriatr Psychiatry 12(6): 554-70.(2004);
[31]
Yeo JM, Lim X, Khan Z, Pal S. Systematic review of the diagnostic utility of SPECT imaging in dementia. Eur Arch Psychiatry Clin Neurosci 263(7): 539-52.(2013);
[32]
Jagust W, Thisted R, Devous MD Sr, Van Heertum R, Mayberg H, Jobst K, et al. SPECT perfusion imaging in the diagnosis of Alzheimer’s disease: a clinical-pathologic study. Neurology 56(7): 950-6.(2001);
[33]
Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, et al. Frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria. Neurology 51(6): 1546-54.(1998);
[34]
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12): 1863-72.(2005);
[35]
Beach TG, Adler CH, Lue L, Sue LI, Bachalakuri J, Henry-Watson J, et al. Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol 117(6): 613-34.(2009);
[36]
Kemp PM, Hoffmann SA, Tossici-Bolt L, Fleming JS, Holmes C. Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nucl Med Commun 28(6): 451-6.(2007);
[37]
Berti V, Pupi A, Mosconi L. PET/CT in diagnosis of dementia. Ann N Y Acad Sci 1228: 81-92.(2011);
[38]
Sinha N, Firbank M, O’Brien JT. Biomarkers in dementia with Lewy bodies: a review. Int J Geriatr Psychiatry 27(5): 443-53.(2012);
[39]
O’Brien JT, Firbank MJ, Davison C, Barnett N, Bamford C, Donaldson C, et al. 18F-FDG PET and perfusion SPECT in the diagnosis of Alzheimer and Lewy body Dementias. J Nucl Med 55(12): 1959-65.(2014);
[40]
Davison CM, O’Brien JT. A comparison of FDG-PET and blood flow SPECT in the diagnosis of neurodegenerative dementias: a systematic review. Int J Geriatr Psychiatry 29(6): 551-61.(2014);
[41]
Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 35(9): 1528-37.(1994);
[42]
Sugiura M, Kawashima R, Sadato N, Senda M, Kanno I, Oda K, et al. Anatomic validation of spatial normalization methods for PET. J Nucl Med 40(2): 317-22.(1999);
[43]
Fox PT, Perlmutter JS, Raichle ME. A stereotactic method of anatomical localization for positron emission tomography. J Comput Assist Tomogr 9(1): 141-53.(1985);
[44]
Talairach J, Tournoux P. Co-planar stereotactic atlas of the human brain. Stuttgart: Thieme (1998).
[45]
Friston KJ, Frith CD, Liddle PF, Frackowiak RS. Plastic transformation of PET images. J Comput Assist Tomogr 15(4): 634-9.(1991);
[46]
Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: linear scaling and nonlinear warping of functional brain images. J Nucl Med 35(9): 1528-37.(1994);
[47]
Kogure D, Matsuda H, Ohnishi T, Asada T, Uno M, Kunihiro T, et al. Longitudinal evaluation of early Alzheimer’s disease using brain perfusion SPECT. J Nucl Med 41(7): 1155-62.(2000);
[48]
Van Laere KJ, Warwick J, Versijpt J, Goethals I, Audenaert K, Van Heerden B, et al. Analysis of clinical brain SPECT data based on anatomic standardization and reference to normal data: an ROC-based comparison of visual, semiquantitative, and voxel-based methods. J Nucl Med 43(4): 458-69.(2002);
[49]
Dougall N, Nobili F, Ebmeier KP. Predicting the accuracy of a diagnosis of Alzheimer’s disease with 99mTc HMPAO single photon emission computed tomography. Psychiatry Res 131(2): 157-68.(2004);
[50]
Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 36(7): 1238-48.(1995);
[51]
Tang BN, Minoshima S, George J, Robert A, Swine C, Laloux P, et al. Diagnosis of suspected Alzheimer’s disease is improved by automated analysis of regional cerebral blood flow. Eur J Nucl Med Mol Imaging 31(11): 1487-94.(2004);
[52]
Ishii K, Kanda T, Uemura T, Miyamoto N, Yoshikawa T, Shimada K. i. Computer-assisted diagnostic system for neurodegenerative dementia using brain SPECT and 3D-SSP. Eur J Nucl Med Mol Imaging 36(5): 831-40.(2009);
[53]
Imabayashi E, Matsuda H, Asada T, Ohnishi T, Sakamoto S, Nakano S, et al. Superiority of 3-dimensional stereotactic surface projection analysis over visual inspection in discrimination of patients with very early Alzheimer’s disease from controls using brain perfusion SPECT. J Nucl Med 45(9): 1450-7.(2004);
[54]
Matsuda H, Mizumura S, Nagao T, Ota T, Iizuka T, Nemoto K, et al. Automated discrimination between very early Alzheimer disease and controls using an easy Z-score imaging system for multicenter brain perfusion single-photon emission tomography. AJNR Am J Neuroradiol 28(4): 731-6.(2007);
[55]
Waragai M, Yamada T, Matsuda H. Evaluation of brain perfusion SPECT using an easy Z-score imaging system (eZIS) as an adjunct to early-diagnosis of neurodegenerative diseases. J Neurol Sci 260(1-2): 57-64.(2007);
[56]
Tranfaglia C, Palumbo B, Siepi D, Sinzinger H, Parnetti L. Semi-quantitative analysis of perfusion of Brodmann areas in the differential diagnosis of cognitive impairment in Alzheimer’s disease, fronto-temporal dementia and mild cognitive impairment. Hell J Nucl Med 12(2): 110-4.(2009);
[57]
Santra A, Sinha GK, Neogi R, Thukral RK. (99m)Tc-hexamethyl propyleneamine oxime brain perfusion single photon emission computed tomography in characterization of dementia: an initial experience in Indian clinical practice. World J Nucl Med 13(2): 120-7.(2014);
[58]
Valotassiou V, Papatriantafyllou J, Sifakis N, Tzavara C, Tsougos I, Psimadas D, et al. Brain perfusion SPECT with Brodmann areas analysis in differentiating frontotemporal dementia subtypes. Curr Alzheimer Res 11(10): 941-54.(2014);
[59]
Booij J, Tissingh G, Winogrodzka A, van Royen EA. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 26(2): 171-82.(1999);
[60]
Booij J, Tissingh G, Boer GJ, Speelman JD, Stoof JC, Janssen AG, et al. [123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson’s disease. J Neurol Neurosurg Psychiatry 62(2): 133-40.(1997);
[61]
Benamer TS, Patterson J, Grosset DG, Booij J, de Bruin K, van Royen E, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 15(3): 503-10.(2000);
[62]
Benamer HT, Patterson J, Wyper DJ, Hadley DM, Macphee GJ, Grosset DG. Correlation of Parkinson’s disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord 15(4): 692-8.(2000);
[63]
Antonini A. The role of 123I-ioflupane SPECT dopamine transporter imaging in the diagnosis and treatment of patients with dementia with Lewy bodies. Neuropsychiatr Dis Treat 3(3): 287-92.(2007);
[64]
Piggott MA, Marshall EF, Thomas N, Lloyd S, Court JA, Jaros E, et al. Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer’s and Parkinson’s diseases: rostrocaudal distribution. Brain 122(Pt 8): 1449-68.(1999);
[65]
Walker Z, Costa DC, Ince P, McKeith IG, Katona CL. In-vivo demonstration of dopaminergic degeneration in dementia with Lewy bodies. Lancet 54(9179): 646-7.(1999);
[66]
O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61(6): 919-25.(2004);
[67]
Walker Z, Costa DC, Walker RW, Shaw K, Gacinovic S, Stevens T, et al. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using a dopaminergic presynaptic ligand. J Neurol Neurosurg Psychiatry 73(2): 134-40.(2002);
[68]
Walker Z, Jaros E, Walker RW, Lee L, Costa DC, Livingston G, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry 78(11): 1176-81.(2007);
[69]
McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, et al. DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol 6(4): 305-13.(2007);
[70]
McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al. Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65(12): 1863-72.(2005);
[71]
O’Brien JT, Colloby S, Fenwick J, Williams ED, Firbank M, Burn D, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol 61(6): 919-25.(2004);
[72]
Walker Z, Costa DC, Walker RW, Lee L, Livingston G, Jaros E, et al. Striatal dopamine transporter in dementia with Lewy bodies and Parkinson disease: a comparison. Neurology 62(9): 1568-72.(2004);
[73]
Papathanasiou ND, Boutsiadis A, Dickson J, Bomanji JB. Diagnostic accuracy of 123I-FP-CIT (DaTSCAN) in dementia with Lewy bodies: a meta-analysis of published studies. Park Relat Disord 18(3): 225-9.(2012);
[74]
Warr L, Walker Z. Identification of biomarkers in Lewy-body disorders. Q J Nucl Med Mol Imaging 56(1): 39-54.(2012);
[75]
Walker Z, Moreno E, Thomas A, Inglis F, Tabet N, Rainer M, et al. DaTSCAN DLB Phase 4 Study Group. Clinical usefulness of dopamine transporter SPECT imaging with 123I-FP-CIT in patients with possible dementia with Lewy bodies: randomised study. Br J Psychiatry 206(2): 145-52.(2015);
[76]
Morgan S, Kemp P, Booij J, Costa DC, Padayachee S, Lee L, et al. Differentiation of frontotemporal dementia from dementia with Lewy bodies using FP-CIT SPECT. J Neurol Neurosurg Psychiatry 83(11): 1063-70.(2012);
[77]
Spehl TS, Frings L, Hellwig S, Weiller C, Hüll M, Meyer PT, et al. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer’s dementia. Clin Nucl Med 40(1): e27-33.(2015);
[78]
Darcourt J, Booij J, Tatsch K, Varrone A, Vander Borght T, Kapucu OL, et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur J Nucl Med Mol Imaging 37(2): 443-50.(2010);
[79]
Djang DS, Janssen MJ, Bohnen N, Booij J, Henderson TA, Herholz K, et al. SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT. J Nucl Med 53(1): 154-63.(2012);
[80]
Filippi L, Manni C, Pierantozzi M, Brusa L, Danieli R, Stanzione P, et al. 123I-FP-CIT semi-quantitative SPECT detects preclinical bilateral dopaminergic deficit in early Parkinson’s disease with unilateral symptoms. Nucl Med Commun 26(5): 421-6.(2005);
[81]
Stokkel MP, Dibbets-Schneider P, Koestering E, Dragoiescu C, Blokland KA. Reproducibility of a standardized quantitative analysis using fixed regions of interest to differentiate movement disorders on 123I-FP-CIT SPECT. J Nucl Med Technol 35(1): 21-6.(2007);
[82]
Goethals I, Dobbeleir A, Ham H, Santens P, D’Asseler Y. Validation of a resolution-independent method for the quantification of 123I-FP-CIT SPECT scans. Nucl Med Commun 28(10): 771-4.(2007);
[83]
Tossici-Bolt L, Hoffmann SM, Kemp PM, Mehta RL, Fleming JS. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging 33(12): 1491-9.(2006);
[84]
Calvini P, Rodriguez G, Inguglia F, Mignone A, Guerra UP, Nobili F. The basal ganglia matching tools package for striatal uptake semi-quantification: description and validation. Eur J Nucl Med Mol Imaging 34(8): 1240-53.(2007);
[85]
Scherfler C, Nocker M. Dopamine transporter SPECT: how to remove subjectivity? Mov Disord 24(2): S721-4.(2007);
[86]
Tondeur MC, Hambye AS, Dethy S, Ham HR. Interobserver reproducibility of the interpretation of I-123 FP-CIT single-photon emission computed tomography. Nucl Med Commun 31(8): 717-25.(2010);
[87]
Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med 54(8): 1331-8.(2013);
[88]
Nobili F, Naseri M, De Carli F, Asenbaum S, Booij J, Darcourt J, et al. Automatic semi quantification of [123I]FP-CIT SPECT scans in healthy volunteers using BasGan version 2: results from the ENC-DAT database. Eur J Nucl Med Mol Imaging 40(4): 565-73.(2013);
[89]
Varrone A, Dickson JC, Tossici-Bolt L, Sera T, Asenbaum S, Booij J, et al. European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis. Eur J Nucl Med Mol Imaging 40(2): 213-27.(2013);
[90]
Kaasinen V, Joutsa J, Noponen T, Johansson J, Seppänen M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson’s disease. Neurobiol Aging 36(4): 1757-63.(2015);
[91]
Palumbo B, Fravolini ML, Nuvoli S, Spanu A, Paulus KS, Schillaci O, et al. Comparison of two neural network classifiers in the differential diagnosis of essential tremor and Parkinson’s disease by (123)I-FP-CIT brain SPECT. Eur J Nucl Med Mol Imaging 7(11): 2146-53.(2010);
[92]
Skanjeti A, Castellano G, Elia BO, Zotta M, Dazzara F, Manfredi M, et al. Multicenter Semiquantitative Evaluation of (123) I-FP-CIT Brain SPECT. J Neuroimaging 25(6): 1023-9.(2015);
[93]
Lamotte G, Morello R, Lebasnier A, Agostini D, Defer GL. Accuracy and cutoff values of delayed heart to mediastinum ratio with (123)I-metaiodobenzylguanidine cardiac scintigraphy for Lewy body disease diagnoses. BMC Neurol 15: 83.(2015);
[94]
Walker RW, Walker Z. Dopamine transporter single photon emission computerized tomography in the diagnosis of dementia with Lewy bodies. Mov Disord 24(2): S754-9.(2009);
[95]
Stocchi F, Olanow CW. Neuroprotection in Parkinson’s disease: clinical trials. Ann Neurol 53(3): S87-97.(2003);
[96]
Palumbo B. Brain tumour recurrence: brain single-photon emission computerized tomography, PET and proton magnetic resonance spectroscopy. Nucl Med Commun 29(8): 730-5.(2008);
[97]
Kapur S. Neuroimaging and drug development: an algorithm for decision making. J Clin Pharmacol 64S-71S.(2001);
Related Books
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Frontiers in Clinical Drug Research-Dementia
Frontiers in Clinical Drug Research - CNS and Neurological Disorders
Article Metrics
23
5